Cartilage News and Research

RSS

Cartilage is a stiff yet flexible connective tissue found in many areas in the bodies of humans and other animals, including the joints between bones, the rib cage, the ear, the nose, the elbow, the knee, the ankle, the bronchial tubes and the intervertebral discs.

Novartis informs Emisphere on First Interpretable Results of two-year Phase III Study 2301 in osteoarthritis

Emisphere Technologies, Inc. announced today that Novartis Pharma AG provided Emisphere with information regarding the First Interpretable Results of the two-year Phase III Study 2301 in osteoarthritis conducted by its license partner Nordic Bioscience with oral calcitonin (SMC021).

25 Oct 2010

AlloSource receives Foothills Award from CPEx

AlloSource, one of the nation's largest non-profit providers of skin, bone and soft tissue allografts for use in surgical procedures and the world's largest processor of live cellular bone growth substitutes, today announced its receipt of the Foothills Award from Colorado Performance Excellence (CPEx), a statewide non-profit that helps organizations improve performance and achieve results.

22 Oct 2010

Novartis releases study results on oral calcitonin for treatment of osteoarthritis: Unigene Laboratories

Unigene Laboratories, Inc. announced today that Novartis has released information on the first of two studies on oral calcitonin for the treatment of osteoarthritis conducted by its license partner Nordic Bioscience. The recently completed Study 2301, which assesses the safety and efficacy of oral calcitonin in the treatment of knee osteoarthritis, had three co-primary endpoints.

22 Oct 2010

Kensey Nash 2011 first quarter decreases 14% to $17.0 million

Kensey Nash Corporation , a medical device company primarily focused on regenerative medicine for a wide range of medical procedures, today reported the results for its first quarter ended September 30, 2010.

21 Oct 2010

Lubricin reduces wear to bone cartilage

A team of researchers in North Carolina has discovered that lubricin, a synovial fluid glycoprotein, reduces wear to bone cartilage. This result, which has implications for the treatment of sufferers of osteoarthritis, will be presented today at the AVS 57th International Symposium & Exhibition, taking place this week at the Albuquerque Convention Center in New Mexico.

21 Oct 2010

Valensa enters agreement with Mercola for Flex Pro ES formulation

Valensa International and Mercola Health Resources, LLC announced today that they have entered into a license and supply agreement that provides Mercola Health Resources with Valensa's new Flex Pro ES(TM) joint health formulation.

21 Oct 2010

Study: p63 gene stifles spread of cancer

Long overshadowed by p53, its famous tumor-suppressing sibling, the p63 gene does the tougher, important job of stifling the spread of cancer to other organs, researchers at The University of Texas MD Anderson Cancer Center report in the Oct. 21 issue of Nature.

21 Oct 2010

BioMarin announces BMN-111 program for treatment of achondroplasia

BioMarin Pharmaceutical Inc. today announced its program for BMN-111, a peptide therapeutic for the treatment of achondroplasia. BioMarin plans to file an IND in the fourth quarter of 2011 and to initiate a Phase 1 clinical trial by the first quarter of 2012.

19 Oct 2010

Nanotope enters agreement with Smith & Nephew to develop cartilage regeneration product

Arrowhead Research Corporation today announced that its portfolio company, Nanotope, Inc., has entered into an agreement with Smith & Nephew, Inc., a member of the Smith & Nephew plc group to develop a cartilage regeneration product for human healthcare markets using a subset of its proprietary regenerative medicine technology.

18 Oct 2010

Interim data from HyQ Phase III clinical study in primary immune deficiency presented at 26th ESID

Data from interim analyses of a Phase III clinical study in patients with primary immune deficiency (PID) who received Baxter's HyQ were presented at the 26th meeting of the European Society for Immunodeficiencies (ESID) in Istanbul, Turkey. HyQ is an immune globulin (IG) therapy facilitated subcutaneously by recombinant human hyaluronidase, a dispersion and permeation enhancer.

From Baxter International Inc. 6 Oct 2010

ISTO announces completion of enrollment in NuQu Phase I clinical study for discogenic back pain

ISTO Technologies, Inc., an orthobiologics company with a cell-based platform for cartilage regeneration, announced today the completion of patient enrollment in the Phase I clinical study for NuQu™, an injectable formulation of juvenile chondrocytes designed for the treatment of discogenic back pain. The study included 15 patients enrolled at two clinical sites. All patients enrolled in the trial suffered from persistent discogenic back pain and disability despite undergoing previous traditional conservative therapy.

5 Oct 2010

Researchers create new cell lines from mesenchymal stem cells

Biomedical researchers at the University at Buffalo have engineered adult stem cells that scientists can grow continuously in culture, a discovery that could speed development of cost-effective treatments for diseases including heart disease, diabetes, immune disorders and neurodegenerative diseases.

4 Oct 2010

Study shows Artelon scaffold improves cartilage repair outcome

A laboratory study (in vitro) and an animal study, which are currently being presented at the 9th World Congress of the International Cartilage Repair Society, demonstrate that Artelon functions as a scaffold for cells in conjunction with cartilage repair.

29 Sep 2010

Galapagos initiates phase II clinical study of GLPG0259 drug in RA patients

Galapagos NV announced today that it has started a Phase II clinical study for the Company's flagship program GLPG0259, a novel drug being developed for rheumatoid arthritis. In this clinical trial, the safety and efficacy of this novel candidate drug will be tested in RA patients. Galapagos plans to announce interim results by the middle of next year and complete the trial by the end of 2011.

28 Sep 2010

Researchers publish evidence behind evolution of jaws in vertebrates

A half-billion years ago, vertebrates lacked the ability to chew their food. They did not have jaws. Instead, their heads consisted of a flexible, fused basket of cartilage.This week, an international team of researchers led by a faculty member from the University of Colorado at Boulder published evidence that three genes in jawless vertebrates might have been key to the development of jaws in higher vertebrates.

27 Sep 2010

Calcitonin combination therapy may help treat osteoarthritis: Study

Tarsa Therapeutics, Inc. and Unigene Laboratories, Inc. today reported preclinical data showing that calcitonin may have synergistic effects in combination with other drugs in reducing the collagen degradation associated with osteoarthritis.

27 Sep 2010

Interleukin Genetics announces clinical study data on osteoarthritis progression

Interleukin Genetics, Inc. and the Thurston Arthritis Research Center at the University of North Carolina at Chapel Hill announced today findings from a large clinical study to evaluate the role of genetic factors in osteoarthritis progression which showed patients with radiographic evidence of knee osteoarthritis who inherited a specific pattern of genetic variations in the interleukin-1 receptor antagonist (IL-1Ra) gene were almost twice as likely to progress to severe disease as other patients.

23 Sep 2010

Study links progressive osteoarthritis to IL-1Ra gene variations

Scientists from University of North Carolina at Chapel Hill School of Medicine and Interleukin Genetics, Inc. announced today findings from a large clinical study to evaluate the role played by genetic factors in the worsening of osteoarthritis.

22 Sep 2010

New genes associated with osteoarthritis progression

21 Sep 2010

Nine new projects to uncover link between diet and health

9 new projects aimed at uncovering links between diet and health and worth a total of £4M are announced today by a public-private partnership of three research councils (BBSRC, EPSRC and MRC) and 13 food and drink companies. The new projects tackle issues such as reducing fat content or proportion of saturated fat in food, fortification with bioactive compounds including Omega-3 polyunsaturated fatty acids and antioxidants and increasing the dietary fibre in white bread.

15 Sep 2010